SUSTAIN-6 was designed as a non-inferiority trial to assess the CV safety of semaglutide versus placebo. 1 The trial included >3000 patients with T2D who had established CV disease or were aged ≥60 years with ≥1 CV risk factor.1 This module details the CV endpoints and safety results from the trial.
SUSTAIN-6 Trial
SUSTAIN-6: study design
SUSTAIN-6: baseline characteristics (1/2)
SUSTAIN-6: baseline characteristics (2/2)
SUSTAIN-6: renal function at baseline
SUSTAIN-6: glucose-lowering medications at baseline
SUSTAIN-6: CV medications at baseline (1/2)
SUSTAIN-6: CV medications at baseline (2/2)
SUSTAIN-6: primary outcome 3P-MACE
SUSTAIN-6: components of 3P-MACE
SUSTAIN-6: subgroup analysis of 3P-MACE (1/5)
SUSTAIN-6: subgroup analysis of 3P-MACE (2/5)
SUSTAIN-6: subgroup analysis of 3P-MACE (3/5)
SUSTAIN-6: subgroup analysis of 3P-MACE (4/5)
SUSTAIN-6: subgroup analysis of 3P-MACE (5/5)
SUSTAIN-6: CV death
SUSTAIN-6: non-fatal MI
SUSTAIN-6: non-fatal stroke
SUSTAIN-6: hospitalisation for heart failure
SUSTAIN-6: summary of all CV endpoints
SUSTAIN-6: microvascular endpoints
SUSTAIN-6: diabetic retinopathy complications
SUSTAIN-6: new or worsening nephropathy (1/2)
SUSTAIN-6: new or worsening nephropathy (2/2)
SUSTAIN-6: metabolic parameters (1/3)
SUSTAIN-6: metabolic parameters (2/3)
SUSTAIN-6: heart rate
SUSTAIN-6: metabolic parameters (3/3)
SUSTAIN-6: glucose-lowering medications introduced post-baseline, and hypoglycaemic events